• The Future of Blood Testing Lies in Understanding the Whole Body

    Apr 03 | Diagnostics World | For decades, blood testing innovation has focused on improving patient testing for earlier and faster intervention. Advances in sequencing, automation, and molecular testing have dramatically improved our ability to biologically monitor patients. But as powerful as these technologies have become, they often still operate within a limited framework: they look for a biomarker panel that constitutes a single signal tied to a single disease. More

  • Handheld AI-Powered Eye Scanner Could Reach More Patients

    Apr 02 | Diagnostics World | Research out of Tohoku University in Sendai, Japan, provides a model for easily assessing front of the eye health outside of hospitals. The research team envisions employing the portable AI-powered scanning slit-light device in remote eye-screening camps, elderly-care facilities, pharmacies, or even train stations to make ophthalmic care more accessible, so patients can be assessed any place and any time. More

  • Roche ApoE4 Blood Test

    Apr 01 | Diagnostics World | Roche has received CE Mark approval for its Elecsys Apolipoprotein E4 biomarker test – the first in-vitro diagnostic (IVD) immunoassay to identify the presence of the ApoE4 gene variant in the bloodstream. More

  • Follow the Money: Precision Genetic Drugs, Engineering Synthetic Macrocyclic Peptides, More

    Mar 25 | Diagnostics World | BreezeBio, formerly known as GenEdit, advances their NanoGalaxy delivery platform; Unnatural Products develops their proprietary drug discovery platform; and more. More

  • Verily, Samsung Collaboration, PathAI Receives FDA Approval, LinusBio Expands Test Further

    Mar 24 | Diagnostics World | Verily Life Sciences and Samsung Electronics America enter a collaboration; PathAI announces that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to PathAssist Derm; LinusBio announces that ClearStrand-ASD is now available for children up to age 10; and more. More

  • Beyond the Breakthrough: What Alzheimer’s Blood Tests Need Before They Can Truly Change Care

    Mar 20 | Diagnostics World | The gold standard tests — PET scans that visualize amyloid plaques and cerebral spinal fluid (CSF) assays that measure core biomarkers directly — have long been the backbone of accurate Alzheimer’s diagnoses. Next-generation Alzheimer’s blood-based biomarkers are now producing accuracy levels in the greater than 90% sensitivity range, roughly on par with PET and CSF. This is not just a scientific milestone — it feels like a shift in what is possible for everyday clinical practice. More

  • Illumina, Labcorp Expand Collaboration, Develop New IVD Tests

    Mar 18 | Diagnostics World | Illumina and Labcorp today announced an expanded collaboration to develop applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include distributed cancer biomarker test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need. More

  • Simple Blood Test Predicts Survival Based on Causal Biomarkers

    Mar 17 | Diagnostics World | Aging has increasingly been viewed as a modifiable target for therapeutic intervention, an encouraging idea that was recently reaffirmed with the development of a simple blood test for predicting survival. The biomarkers being measured include five piwi-interacting RNAs, together with high density lipoprotein particle number and the ability to do instrumental activities of daily living, such as the ability to independently shop and do housework. More

  • Droplet Biosciences Turns Post-Op Waste Into Life-Saving Data

    Mar 11 | Diagnostics World |Droplet Bioscience’s validated clinical test analyzes post-surgical lymphatic fluid for circulating tumor DNA. In a process sped up by NVIDIA Parabricks, the test can provide adjuvant-informing results in about a week. More

  • The GLP-1 Era: It’s More Than Just Weight

    Mar 10 | Diagnostics World News | The healthcare industry has a weight problem—a weight bias problem, according to Ashley Koff, RD, founder of The Better Nutrition Program. During her plenary keynote at February’s Integrative Healthcare Symposium, Koff addressed the urgent need to rethink approaches to weight, metabolic health, and the use of GLP-1 medications. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more